Illinois 2023-2024 Regular Session

Illinois Senate Bill SR0028 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	SR0028LRB103 25358 MST 51703 r SR0028 LRB103 25358 MST 51703 r
2	2	SR0028 LRB103 25358 MST 51703 r
3	3	1 SENATE RESOLUTION
4	4	2 WHEREAS, The Illinois Department of Public Health's May
5	5	3 2022 report recorded 3,013 fatalities that occurred in 2021
6	6	4 due to opioid overdoses; and
7	7	5 WHEREAS, The 3,013 Illinois opioid overdose deaths
8	8	6 represent a 2.3% increase from 2020 and a 35.8% spike from
9	9	7 2019; and
10	10	8 WHEREAS, In 2021, toxicology testing found that 2,672
11	11	9 (89%) of the opioid fatalities involved a synthetic opioid,
12	12	10 such as fentanyl; and
13	13	11 WHEREAS, A 4 milligram naloxone hydrochloride nasal spray
14	14	12 has been the principal tool used by bystanders and emergency
15	15	13 medical services (EMS) to revive an individual from an
16	16	14 overdose episode; and
17	17	15 WHEREAS, A study, published in the Harm Reduction Journal
18	18	16 in May 2022, surveyed 125 adult U.S. residents who had been
19	19	17 administered a 4 milligram naloxone nasal spray during an
20	20	18 opioid overdose and found that 78% used 2 or more doses and 30%
21	21	19 used 3 or more doses of naloxone; and
22	22	20 WHEREAS, A 2021 Johns Hopkins Bloomberg School of Public
23	23
24	24
25	25
26	26	SR0028 LRB103 25358 MST 51703 r
27	27
28	28
29	29	SR0028- 2 -LRB103 25358 MST 51703 r SR0028 - 2 - LRB103 25358 MST 51703 r
30	30	SR0028 - 2 - LRB103 25358 MST 51703 r
31	31	1 Health study published in the Harm Reduction Journal reported
32	32	2 on a survey of 171 people who use opioids in suburban Maryland;
33	33	3 sixty-one (35.7%) of these people who use opioids had received
34	34	4 take-home naloxone over a six month period; 57% of naloxone
35	35	5 recipients used it to reverse an overdose; 79% of overdose
36	36	6 reversals reported needing more than 2 doses; and
37	37	7 WHEREAS, Published by the National Library of Medicine, a
38	38	8 study of the National Emergency Medical Services Information
39	39	9 System Database of more than 10,000 EMS agencies across 47
40	40	10 states with 946,000 calls giving naloxone shows that use of
41	41	11 naloxone multi-dosing by EMS increased 54% over five-years,
42	42	12 from 18.4% to 28.4% in 2020; and
43	43	13 WHEREAS, On April 30, 2021, the U.S. Food and Drug
44	44	14 Administration approved a higher 8 milligram dose of naloxone
45	45	15 hydrochloride nasal spray product to treat opioid overdose;
46	46	16 and
47	47	17 WHEREAS, On October 19, 2021, the U.S. Food and Drug
48	48	18 Administration also approved a single-dose, pre-filled syringe
49	49	19 that delivers 5 milligrams of naloxone hydrochloride solution
50	50	20 through intramuscular (in the muscle) or subcutaneous (under
51	51	21 the skin) injection; and
52	52	22 WHEREAS, Thirty-four U.S. states have open access to the 8
53	53
54	54
55	55
56	56
57	57
58	58	SR0028 - 2 - LRB103 25358 MST 51703 r
59	59
60	60
61	61	SR0028- 3 -LRB103 25358 MST 51703 r SR0028 - 3 - LRB103 25358 MST 51703 r
62	62	SR0028 - 3 - LRB103 25358 MST 51703 r
63	63	1 milligram naloxone nasal spray on their Naloxone Standing
64	64	2 Orders, including Ohio, Kentucky, Iowa, Pennsylvania,
65	65	3 Massachusetts, New Jersey, Virginia, Alabama, Florida,
66	66	4 Tennessee, Colorado, Alaska, New Hampshire, Illinois, Arizona,
67	67	5 Kansas, California, Texas, Georgia, South Carolina, North
68	68	6 Carolina, West Virginia, Michigan, Connecticut, Oklahoma,
69	69	7 Minnesota, Maine, Louisiana, Nevada, Idaho, Oregon, Nebraska,
70	70	8 and Vermont; and
71	71	9 WHEREAS, Thirteen state government agencies have purchased
72	72	10 the 8 milligram naloxone nasal spray, including Alabama,
73	73	11 Alaska, Colorado, Florida, Idaho, Iowa, Kentucky, New
74	74	12 Hampshire, Ohio, Pennsylvania, Tennessee, Wisconsin, and West
75	75	13 Virginia; and
76	76	14 WHEREAS, The U.S. Veterans Administration added the 8
77	77	15 milligram naloxone nasal spray to the National Formulary in
78	78	16 November 2021; and
79	79	17 WHEREAS, Seventy percent of the number of lives covered by
80	80	18 commercial insurance in the U.S. can access the 8 milligram
81	81	19 naloxone nasal spray; and
82	82	20 WHEREAS, Ninety percent of the number of lives covered by
83	83	21 Medicaid insurance in the U.S. (40 states) can access the 8
84	84	22 milligram naloxone nasal spray, including Illinois; and
85	85
86	86
87	87
88	88
89	89
90	90	SR0028 - 3 - LRB103 25358 MST 51703 r
91	91
92	92
93	93	SR0028- 4 -LRB103 25358 MST 51703 r SR0028 - 4 - LRB103 25358 MST 51703 r
94	94	SR0028 - 4 - LRB103 25358 MST 51703 r
95	95	1 WHEREAS, The current cost of the 4 milligram naloxone
96	96	2 nasal spray is $5.93 per milligram and the 8 milligram version
97	97	3 is $3.75 per milligram, or 36.7 percent less; and
98	98	4 WHEREAS, Being good stewards of taxpayer money is a
99	99	5 priority for the Illinois General Assembly; therefore, be it
100	100	6 RESOLVED, BY THE SENATE OF THE ONE HUNDRED THIRD GENERAL
101	101	7 ASSEMBLY OF THE STATE OF ILLINOIS, that we strongly urge the
102	102	8 Illinois Department of Human Services to review the value of
103	103	9 expanding its naloxone tool kit to include all U.S. Food and
104	104	10 Drug Administration-approved versions of naloxone or other
105	105	11 FDA-approved products to fight the Illinois opioid epidemic;
106	106	12 and be it further
107	107	13 RESOLVED, That suitable copies of this resolution be
108	108	14 delivered to the Governor of Illinois, the Governor's Chief
109	109	15 Behavioral Health Officer, the Secretary of the Department of
110	110	16 Human Services, and the Director of the Division of Substance
111	111	17 Use, Prevention and Recovery.
112	112
113	113
114	114
115	115
116	116
117	117	SR0028 - 4 - LRB103 25358 MST 51703 r